Caplin Point Laboratories (524742) Stock Overview
Engages in the development, production, marketing, and export of generic formulations and branded products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 524742 from our risk checks.
524742 Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Caplin Point Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,754.75 |
| 52 Week High | ₹2,874.00 |
| 52 Week Low | ₹1,502.45 |
| Beta | 0.37 |
| 1 Month Change | 11.05% |
| 3 Month Change | 16.55% |
| 1 Year Change | 22.76% |
| 3 Year Change | 163.75% |
| 5 Year Change | 216.38% |
| Change since IPO | 1,252,059.09% |
Recent News & Updates
Recent updates
524742: Upcoming Dividend And Board Decisions Will Shape A Measured Outlook
Analysts have raised their fair value estimate for Caplin Point Laboratories from ₹2,508 to ₹2,765, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What’s in the News for Caplin Point Laboratories A board meeting is scheduled for August 12, 2026, to review unaudited standalone and consolidated financial results for the quarter ended June 30, 2026.Latin American Expansion And Global Scaling Will Secure Enduring Success
With both future P/E and net profit margin holding steady, analyst valuation for Caplin Point Laboratories remains unchanged, maintaining the price target at ₹2508. What's in the News Board meeting scheduled to consider quarterly unaudited financial results for the quarter ended June 30, 2025.
Expansion Into Latin America And US Injectables Will Strengthen Future Prospects
Expanding into Latin America and the U.S. market aims to drive significant revenue growth through international expansion and front-end presence.Shareholder Returns
| 524742 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.0% | 0.2% | -1.4% |
| 1Y | 22.8% | 14.5% | -1.2% |
Return vs Industry: 524742 exceeded the Indian Pharmaceuticals industry which returned 14.5% over the past year.
Return vs Market: 524742 exceeded the Indian Market which returned -1.2% over the past year.
Price Volatility
| 524742 volatility | |
|---|---|
| 524742 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 3.4% |
Stable Share Price: 524742 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524742's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 4,199 | Sridhar Ganesan | www.caplinpoint.net |
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel, capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, ophthalmic droppers, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags.
Caplin Point Laboratories Limited Fundamentals Summary
| 524742 fundamental statistics | |
|---|---|
| Market cap | ₹209.39b |
| Earnings (TTM) | ₹6.65b |
| Revenue (TTM) | ₹22.87b |
Is 524742 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524742 income statement (TTM) | |
|---|---|
| Revenue | ₹22.87b |
| Cost of Revenue | ₹9.16b |
| Gross Profit | ₹13.72b |
| Other Expenses | ₹7.06b |
| Earnings | ₹6.65b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 87.53 |
| Gross Margin | 59.97% |
| Net Profit Margin | 29.09% |
| Debt/Equity Ratio | 0.1% |
How did 524742 perform over the long term?
See historical performance and comparisonDividends
Does 524742 pay a reliable dividends?
See 524742 dividend history and benchmarks| Caplin Point Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | Sep 18 2026 |
| Dividend Pay Date | Oct 24 2026 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 41 days |
Does 524742 pay a reliable dividends?
See 524742 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 05:57 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Caplin Point Laboratories Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Siddhant Khandekar | ICICIdirect.com |